COPD: The role of primary care in effective diagnosis, treatment and management

Primary Care Respiratory Journal

Volumn 12, Issue 1, 2003, Pages 16-20

  Van Schayck, Onno C P ^a   Rabe, Klaus F ^b   Rudolf, Michael ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c EALING HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FORMOTEROL; IPRATROPIUM BROMIDE; SALMETEROL; THEOPHYLLINE DERIVATIVE; TIOTROPIUM BROMIDE;

ANTIBIOTIC THERAPY; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EPIDEMIC; HEALTH CARE COST; HUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; REVIEW; SCREENING; SYMPTOMATOLOGY; TREATMENT PLANNING;

EID: 0038101677     PISSN: 14714418     EISSN: None     Source Type: Journal    
DOI: 10.1038/pcrj.2003.6     Document Type: Review

References (51)

1. Speight AN, Lee DA, Hey EN. Underdiagnosis and undertreatment of asthma in childhood. BMJ 1983;286:1253-6.
2. Levy M. Delay in diagnosing asthma - is the nature of general practice to blame? JR Coll Gen Pract 1986;36:52-3.
3. Brand PL, Rijcken B, Schouten JP, et al. Perception of airway obstruction in a random population sample. Relationship to airway hyperresponsiveness in the absence of respiratory symptoms. Am Rev Respir Dis 1992;146:396-401.
4. Kendrick AH, Higgs CM, Whitfield MJ, et al. Accuracy of perception of severity of asthma: patients treated in general practice. BMJ 1993;307:422-4.
5. van den Boom G, van Schayck CP, Rutten-van Molken MPMH, et al. Active detection of chronic obstructive pulmonary disease and asthma in the general population. Results and economic consequences of the DIMCA program. Am J Respir Crit Care Med 1998;158:1730-8.
6. Zielinski J, Bednarek M. Know the Age of Your Lung Study Group. Early detection of COPD in a high-risk population using spirometric screening. Chest 2001;119:731-6.
7. Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799-805.
8. Blainey D. The cost of acute asthma. how much is preventable? Health Trends 1990-91;22:151-3.
9. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997;349:1498-1504.
10. Peto R, Lopez AD, Boreham J, et al. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet 1992;339:1268-78.
11. World Health Organization. Smoking in China: A time bomb for the 21st Century. Fact Sheet No. 177; August 1997.
12. Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 2000;94:204-13.
13. Calverley P, Sondhi S. The burden of obstructive lung disease in the UK - COPD and asthma. Poster presented at the British Thoracic Society meeting - December 1998. Thorax 1998;53(Suppl 4):A83.
14. Jacobson L, Hertmnan P, Lofdahl CG, et al. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med 2000;94:247-55.
15. National Heart Lung and Blood Institute, Morbidity and Mortality: 2000 Chartbook on Cardiovascular, Lung and Blood Diseases. 2000, US Department of Health and Human Services, Public Health Service, National Institutes of Health: Bethesda, MD, USA.
16. Murray C, Lopez A, eds. Global health statistics: a compendium of incidence, prevalence, and mortality estimates for over 200 conditions. Cambridge, MA, USA: Harvard University Press, 1996:672-5.
17. Stang P, Lydick E, Silberman C, et al. The prevalence of COPD. Using smoking rates to estimate disease frequency in the general population. Chest 2000;117:354S-9S.
18. Tirimanna PRS, van Schayck CP, den Otter JJ, et al. Prevalence of asthma and COPD in general practice in 1992: has it changed since 1977? Br J Gen Pract 1996;46:277-81.
19. Renwick DS, Connolly MJ. Prevalence and treatment of chronic airways obstruction in adults over the age of 45. Thorax 1996;51:164-8.
20. van Schayck CP, van der Heijden FMMA, van den Boom G, et al. Underdiagnosis of asthma: is the doctor or the patient to blame? The DIMCA project. Thorax 2000;55:562-5.
21. van Schayck CP, Loozen J, Wagena E, et al. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ 2002;324:1370-4.
22. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001;163:1256-76.
23. Celli BR. Pulmonary rehabilitation in patients with COPD. Am J Respir Crit Care Med 1995;152:861-4.
24. 1. JAMA 1994;272:1497-505.
25. Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000;161:381-90.
26. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in COPD. N Engl J Med 2000;324:1960-1.
27. 1 and asbestos exposure. Eur Respir J 1998;11:284-90.
28. Rutten-van Molken MPMH, Postma MJ, Joore MA, et al. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med 1999;93:779-87.
29. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058-69.
30. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-65.
31. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
32. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
33. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55.
34. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1993;145:1321-7.
35. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-9.
36. 1 over time in one year clinical trials of tiotropium in COPD. Am J Respir Crit Care Med 2001;163:A280.
37. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998;53:129-36.
38. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23.
39. Dompeling E, van Schayck C, van Grunsven P, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study. Ann Intern Med 1993;118:770-8.
40. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-80.
41. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluficasone propionate in patients with moderate to severe chronic obstructive pulmonary disease. the ISOLDE trial. BMJ 2000;320:1297-303.
42. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-53.
43. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
44. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002;96:700-8.
45. Miravitlles M, Murio C, Guerrero T, et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121:1449-55.
46. Nichol K, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Annals of Internal Medicine 1999;130:397-403.
47. Niewoehner D, Erbland M, Deupree R, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941-7.
48. Decramer M, Lacquet L, Fagard R, et al. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994;150:11-16.
49. Adams SG, Melo J, Luther M, et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000;117:1345-52.
50. Berry M, Rejeski W, Adair N, et al. Exercise Rehabilitation and Chronic Obstructive Pulmonary Disease Stage. Am J Respir Crit Care Med 1999;160:1248-53.
51. Anon. The Science of COPD. GOLD Newsletter, June 2002.Vol. 1, No. 1. http://www.goldcopd.com/newsjune.pdf